The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and ...

The GSK oncology products it has sold on to Novartis were ... Other drugs in the portfolio include Votrient, for renal cell carcinoma, Promacta for thrombocytopenia, HER2+ metastatic breast ...

Formerly known as GlaxoSmithKline ... It is also expanding its antibiotics and vaccines portfolio. Some of its significant products include Gepotidacin, the first completely new antibiotic ...

In this article, in addition to analyzing GSK's financial results for Q4 2024, I also presented an analysis of the most interesting developments in its portfolio. However, that's not all.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

UK drugmaker GSK is struggling to convince the market ... for GSK is to persuade investors it can rebuild its oncology portfolio, after leaving the market in 2015. It subsequently went back ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.